Key result
IV dopexamine dose-dependently increases cardiac index and lowers systemic vascular resistance in chronic heart failure.
Why the study?
The acute haemodynamic and metabolic effects of dopexamine in patients with chronic heart failure were not well characterized.
Does intravenous dopexamine improve acute haemodynamic and metabolic parameters in patients with chronic heart failure?
Does intravenous dopexamine improve acute haemodynamic and metabolic parameters in patients with chronic heart failure?
Intravenous dopexamine acutely improves hemodynamics and myocardial efficiency without significantly increasing myocardial oxygen consumption in patients with chronic heart failure.
Answers are grounded in this paper and cite their sources.
May improve acute hemodynamics in chronic heart failure; hypothesis-generating and should not yet change practice.
Dopexamine, a new compound with postjunctional dopamine receptor activating and beta adrenoceptor agonist properties, was given to 10 patients with chronic heart failure at diagnostic cardiac catheterisation to investigate its acute haemodynamic and metabolic effects. The drug was administered by intravenous infusion in three incremental doses and produced significant dose related increases in cardiac index, stroke volume index, and heart rate and falls in systemic vascular resistance and left ventricular end diastolic pressure; aortic and pulmonary artery pressures were unchanged. Isovolumic phase (max dP/dt and KVmax) and ejection phase (peak aortic blood velocity, maximum acceleration of blood, and maximum rate of change of power with time during ejection) indices of myocardial contractility were all increased by dopexamine but these changes were hard to interpret in the presence of an increase in heart rate. Myocardial efficiency and ejection fraction were both increased and left ventricular end diastolic and end systolic volumes fell. These largely beneficial changes were achieved without a statistically significant increase in myocardial oxygen consumption or disturbance of myocardial metabolic function. Dopexamine was well tolerated but tremor was reported by two patients at the intermediate dose and mild chest pain by two patients at the high dose.
No takes yet. Share an insight, caveat, or question.
Dawson et al. (1985) studied chronic heart failure (n=10). Dopexamine was evaluated on Acute haemodynamic and metabolic effects. Intravenous dopexamine produced significant dose-related increases in cardiac index and stroke volume index, and falls in systemic vascular resistance in patients with chronic heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: